- Sanofi (NASDAQ:SNY) inks agreement with Johnson & Johnson (NYSE:JNJ) unit, Janssen Pharmaceuticals to provide manufacturing support for Janssen's COVID-19 vaccine candidate.
- Once authorized, Sanofi will provide JNJ access to the established infrastructure and expertise of its vaccine manufacturing plant in Marcy l’Etoile, France, to formulate and fill vials of Janssen’s COVID-19 vaccine candidate in 2021, at a rate of ~12M doses per month.
- In addition to the protein-based vaccine being developed with GSK, Sanofi is developing a messenger RNA vaccine in partnership with Translate Bio.
- Preclinical data showed that two immunizations of the mRNA vaccine induced high neutralizing antibody levels specific to the SARS-CoV-2 spike protein. A Phase 1/2 study is expected to start in Q1.
- Earlier in January 2021, Sanofi announced plans to support Pfizer-BioNTech in manufacturing and supply of more than 125M doses their COVID-19 vaccine.
- Also today, the company initiated Phase 2 study of its protein-based COVID-19 jab.